Thalidomide and its analogues (lenalidomide and pomalidomide) are small molecule glutamic acid derivatives of the immunomodulatory drug (IMiD) class. In addition to the immuno-adjuvant and anti-inflammatory properties that define an IMiD, the thalidomide analogues demonstrate an overlapping and diverse range of biological activities, including anti-angiogenic, teratogenic and epigenetic effects. Importantly, the IMiDs possess anti-cancer activity with selectivity for molecularly defined subgroups of hematological malignancies, specifically mature B-cell neoplasms and myelodysplasia with deletion of chromosome 5q. Emerging insight into the pathophysiological drivers of these IMiD-responsive disease states can now be synthesized using previously disclosed IMiD activities and recently discovered thalidomide targets to build unifying models of IMiD mechanism of action. Attention to mechanisms of IMiD-induced clinical toxicities, in particular the recently identified association of lenalidomide with second primary malignancies, provides an additional tool for determination of drug mechanism. This review seeks to define the molecular IMiD targets and biological outputs that underpin their anti-neoplastic activity. It is anticipated that elucidation of important IMiD targets will allow the rational development of new-generation therapeutics with the potential to separate thalidomide-analogue efficacy from clinical toxicity.
INTRODUCTION
Thalidomide analogues are immunomodulatory drugs (IMiDs) with a range of biological effects and putative molecular targets. Thalidomide itself has clinical efficacy as an anti-inflammatory and in a distinct cohort of neoplastic diseases including myelodysplasia (MDS) and multiple myeloma (MM). Despite an initially infamous track record that spans 450 years of human exposure, thalidomide's precise mechanisms of action remain undefined. The diverse biological properties of thalidomide analogues indicate that they might possess divergent mechanistic activities in different diseases. However, thalidomide analogues are not indiscriminate anti-neoplastic agents. Rather, their clinical specificity for a relatively narrow range of clearly definable malignancies suggests a molecularly targeted mechanism of action, intricately linked to the biology of these susceptible disease states.
HISTORICAL NOTE
It is speculated that thalidomide was tested as an antidote to neurotoxins during World War II. This is consistent with thalidomide's initial clinical indication as a sedative with antiemetic properties. 1 Thalidomide was subsequently prescribed for anxiety-and nausea-related conditions, including 'morning sickness' to pregnant women in the 1950s. 1 The ensuing tragedy of birth defects including characteristic limb deformities (dysmelia; stunted limb growth) is well documented and led to the widespread withdrawal of thalidomide from clinical use in 1961. [1] [2] [3] The serendipitous discovery of thalidomide's efficacy in erythema nodosum leprosum (ENL) reawakened interest in the drug. 4, 5 Emerging insight into thalidomide's anti-inflammatory and antiangiogenic activity led to clinical trials in AIDS-related aphthous ulceration, 6, 7 Behcet's syndrome, 8 Crohn's disease, 9 cutaneous lupus 10 and various malignancies. The greatest testament to thalidomide's efficacy was that despite its teratogenicity it was reinstated as an FDA-approved treatment for ENL and MM (in 1998 and 2006, respectively, both available at http://www.fda.gov; last accessed 28/05/2012).
DEFINITION OF IMID
The term IMiD refers to IMiDs licensed by Celgene Corporation (Summit, NJ, USA) for the treatment of several inflammatory and neoplastic diseases. 11 The IMiDs were initially defined by their capacity to inhibit lipopolysaccharide (LPS)-induced monocyte tumor necrosis factor (TNF)-a secretion, and further stratified by their relative effects on other cytokines. Thus 'class I' IMiDs were characterized as broad inhibitors of LPS-induced inflammatory cytokines (for example, TNFa, interleukin (IL)-1b, IL-6 and IL-12), whereas 'class II' compounds (so-called SelCIDS) showed selectivity for TNFa suppression. 12 The SelCIDS are structurally diverse compounds unified by their capacity to antagonize phosphodiesterase-4. Class I (non-phosphodiesterase-4 inhibitory) IMiDs comprise thalidomide and its amino-substituted analogues ( Figure 1 ). These thalidomide analogues have an established antineoplastic role, and will be the focus of this review.
IMID CHEMISTRY AND DEVELOPMENT
Thalidomide (a-(N-phthalimido)glutarimide) is a synthetic glutamic acid derivative. Thalidomide is a chiral molecule; this is biologically important as the S( À ) and R( þ ) enantiomers mediate different activities. 13 However, segregation of biological effects by administration of pure enantiomer is not feasible, as rapid physiological inter-conversion occurs in vivo. 14, 15 The second generation IMiDs CC-5013 (Revlimid, IMiD3, hereafter lenalidomide) and CC-4047 (Actimid, IMiD1, hereafter pomalidomide), are amino-phthaloyl-substituted thalidomide analogues developed on the basis of augmented TNFa inhibition ( Figure 1) . 16, 17 In this respect, second generation IMiDs are up to 50 000 times more potent than thalidomide in vitro 12 and subsequent clinical development has disclosed divergent efficacy and toxicity profiles. Although TNFa suppression is an anti-inflammatory mechanism of IMiDs in ENL, 18 TNFa inhibition is thought to be less relevant in other diseases such as MM (where TNFa-directed therapies do not have efficacy 19 ). Thus, the notion that second generation IMiDs are generally more potent than thalidomide is an oversimplification of thalidomide-analogue biology. Although thalidomide analogues share important immunomodulatory hallmarks (Figure 2 ), they differ in toxicity profiles and clinical efficacy between different disease types. Moreover, thalidomide resistant myeloma can be rescued by treatment by second generation IMiDs, potentially indicating divergent mechanistic activities within the same disease. 20 
IMMUNOLOGICAL HALLMARKS OF IMID ACTIVITY
(1) Suppression of LPS-induced monocyte TNFa production and associated anti-inflammatory activity The IMiDs possess clinically relevant anti-inflammatory activity. ENL is an immune complication of Mycobacterium leprae infection manifesting with fever, skin lesions and multi-organ dysfunction because of antibody complex deposition, complement activation and cytokine dysregulation. 5 Patients with ENL have increased cellular and circulating levels of TNFa that rapidly reduce with thalidomide therapy. 18 Inflammatory complications of other
Mycobacterial infections such as tuberculous meningitis are likewise attenuated in tandem with TNFa levels by IMiDs.
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Thalidomide pre-treatment also abrogates LPS-induced septic shock in animal models of gram-negative septicemia. 22 The in vitro correlate is that thalidomide suppresses the release of TNFa from human monocytes in response to mycobacterial antigens or LPS. 23 TNFa suppression occurs downstream of receptor activation and transcriptional events by acceleration of TNFa mRNA degradation, 24 a mechanism that is specific to thalidomide analogues (Figure 3a) . In addition to enhancing the degradation TNFa mRNA, the IMiDs were recently implicated as having a wider role in translational regulation through downregulation of the eukaryotic elongation initiation factor (eIF)-4E. 25 As the availability of eIF4E is a rate limiting step in the recruitment of mRNAsbearing complex 5 0 -untranslated regions to the ribosome, IMiDs may preferentially downregulate the translation of a range of proteins with 'fragile' 5 0 -untranslated regions. The translational modulation of transcription factors upstream of pro-inflammatory cascades is important in IMiD-related suppression of inflammation. Cyclooxygenase (COX)-2 is a key regulator of arachidonic acid metabolism and rate-limits prostaglandin production. LPSstimulated COX-2 expression is transcriptionally regulated by CCAAT/enhancer-binding protein isoforms 26, 27 that are subject to 5 0 -cap-dependent translation in association with eIF4E. 25 Therefore, the effects of IMiDs on eIF4E-regulated transcription factors are likely to directly regulate the expression of pro-inflammatory gene loci, including COX-2.
The role of thalidomide's anti-inflammatory targets in cancer therapy is uncertain. Non-steroidal COX-2 enzymatic inhibitors have demonstrable anti-cancer activities including anti-angiogenic and anti-metastatic effects. 28 COX-2 inhibitors have efficacy in chemoprophylaxis of familial colorectal polyposis syndromes, 29 but have not shown significant benefit when added to chemotherapy for established COX-2 overexpressing epithelial tumors. 30 Myeloma cells harboring oncogenic RAS mutations also show selective upregulation of COX-2 expression, and in these cells COX-2 inhibition abrogates the protective effects of bone marrow stromal cells on myeloma following chemotherapy treatment. 31 There is some clinical evidence that COX-2 selective inhibition has activity in MM, 32 indicating that the antiinflammatory effects of IMiDs may be relevant in this disease.
(2) Costimulation of T-cells Correlative pre-clinical 33 and clinical 34 evidence suggests that IMiD-mediated T-cell stimulation might augment anti-tumor immunity. The IMiDs modulate cytokine expression in a cell-type and context-dependent manner to either suppress or stimulate the release of selected interleukins. In contrast to the suppression of LPS-induced monocyte inflammatory cytokine release, IMiDs costimulate the release of IL-2 and interferon (IFN)-g from T lymphocytes undergoing CD3 ligation, mitogenic stimulation or in response to dendritic cell presented super-or allo-antigens (Figure 3b) . 35, 36 This results in T-cell proliferation, T-helper-1 subset skewing and immuno-adjuvant anti-tumor effects 33 including augmentation of cytotoxic effector functions. 37, 38 T-cell costimulation by lenalidomide is only partially inhibited by CTLA-4-Ig blockade of the B7/CD28 costimulatory axis. 36 Moreover, lenalidomide induces tyrosine-phosphorylation of CD28, facilitating the recruitment and activation of upstream nodes in intracellular signaling cascades including phosphatidylinositol-3-kinase (PI3K) and nuclear factor (NF)-kB. 36, 37 As neither CD28 nor the IMiDs possess intrinsic kinase activity, an indirect mechanism of CD28 phosphorylation, such as recruitment of other signaling proteins including protein kinase-C (PKC), is postulated. Pomalidomide costimulation activates PKC and PI3K to enhance nuclear translocation of nuclear factor of activated T-cells (NFAT)-2 and activated protein (AP)-1 resulting in increased DNA-binding at the IL-2 promoter. 37, 39 Accordingly, PI3K inhibitors can reduce IL-2 secretion in response to IMiD costimulation. 38, 40 The importance of T-cell help in IMiD responses is highlighted by the suppressive effects of calcineurin inhibitors and corticosteroids on NK-cell cytotoxicity assays. 37, 40, 41 In vivo administration of IMiDs expands circulating NK-cell populations and synergizes with anti-CD20 antibody therapy against B-cell lymphoma xenografts in an NK-cell-dependent fashion. 42 This is potentially explained by the observation that lenalidomide augments antibody-dependent cell cytotoxicity against rituximab (anti-CD20) treated CD20 þ tumor cells. Clinical responses to thalidomide in myeloma patients likewise correspond with increasing numbers of peripheral NK cells. 38 
OTHER DEFINING FEATURES OF THALIDOMIDE ANALOGUES
(1) Anti-angiogenic properties Inflammatory cytokine networks and angiogenic pathways are inherently linked, as neo-vascularization is a consequence of the inflammatory response. Angiogenesis is important in tumor growth and metastasis. Experiments initially designed to dissect thalidomide's teratogenic potential subsequently demonstrated it's anti-angiogenic properties. 43 Thus, suppression of angiogenesis linked IMiD cytokine modulation and anti-cancer activity. However, in contrast to the anti-inflammatory and immunomodulatory properties that are conserved across primate and rodent species', anti-angiogenic effects appear to be relatively species specific. As the teratogenic effects of thalidomide show similar species specificity, it is likely that thalidomide's anti-angiogenic capacity and teratogenicity are also linked ( Figure 4 ). D'Amato et al. 43 first described anti-angiogenic activity of orally administered thalidomide and a related teratogenic analogue, EM-12 that was apparent in experimental systems using rabbit but not chicken cells. Later, the same investigators demonstrated intraperitoneal, but not oral administration of thalidomide inhibited angiogenesis in bFGF and vascular endothelial growth factor (VEGF)-driven cornea micro-pocket assays in the mouse. 13 Conversely, orally administered lenalidomide reduced basic fibroblast growth factor (bFGF)-induced angiogenesis in a rat mesenteric window assay. 44 The observation that route of administration (oral versus intraperitoneal) resulted in divergent anti-angiogenic effects with species specificity supported the notion that in vivo IMiD metabolism modulates anti-angiogenic effects. This hypothesis was further substantiated using in vitro rat aorta and human endothelial cell culture systems that are insensitive to the presence of non-metabolized thalidomide. 45 Here, supplementation of thalidomide with human or rabbit (but not rat) hepatic microsomes resulted in reduced microvessel formation and endothelial cell growth. In a humanized myeloma xenograft model, co-engraftment of human fetal liver cells into a severe combined immunodeficient mouse augmented the antimyeloma activity of thalidomide. 46 Myeloma xenografts from thalidomide-treated, human fetal liver bearing mice showed reduced microvessel density compared with non-fetal liver transplanted hosts. It was concluded that human hepatic metabolism was required for thalidomide's anti-myeloma activity in a mouse. However, this interpretation requires caution as thalidomide metabolites were not assayed, the immunological effects of fetal liver grafts (which contain hematopoietic stem cells) were not accounted for, and thalidomide was administered parenterally rather than orally.
Notwithstanding the putative role of interspecies metabolism in IMiD-mediated suppression of vascularization, thalidomide and its analogues have demonstrable activity against several key angiogenesis regulators. In vivo suppression of pro-angiogenic factors including IL-6, TNFa, VEGF, NF-kB and prostaglandin synthesis is predicted to indirectly downregulate angiogenesis. 12, 26, 47 At the cellular level, the IMiDs downregulate paracrine production of VEGF and IL-6 by both bone marrow stroma and MM cells, alone or in co-culture. 48 VEGF-induced angiogenesis is modulated by intracellular pro-survival signaling pathways and sphingolipid metabolism. 44, 49 Thalidomide activates neutral sphingomyelinase to generate ceramide in human umbilical vein endothelial cells resulting in both decreased cell growth and reduced expression of the VEGF receptors, neurophilin-1 and FLK-1 ( Figure 4) . 49 Lenalidomide downregulates the migratory response of human umbilical vein endothelial cells to VEGF and bFGF. 44 Here, reduced endothelial cell migration correlated with downregulation of AKT phosphorylation, indicating that lenalidomide might uncouple the permissive effects of VEGF-receptor ligation from intracellular signaling pathways. Together, these results indicate that the IMiDs modulate angiogenesis at multiple levels including systemic cytokine networks, local tumor/stroma interactions, surface expression of VEGF receptors and intracellular signaling pathways thereof.
(2) Teratogenicity Intense scientific activity has been dedicated to determining the molecular mechanisms of thalidomide teratogenicity. 50 From a translational perspective, a non-teratogenic yet efficacious IMiD would be highly desirable. Indeed the thalidomide enantiomers, metabolites and analogues vary in their teratogenic potential 51 and the anti-angiogenic and immunomodulatory properties of IMiDs appear to be separable. 52 Whether the anti-neoplastic activities of IMiDs are separable from teratogenic effects remains a point of conjecture. Proposed embryotoxic mechanisms include effects on angiogenesis, 51 intracellular signaling, 53-55 gene regulation 56 and the induction of oxidative stress. 57 For an excellent synopsis that attempts to unify existing conceptual frameworks, the reader is directed to a recent review by Ito et al. 50 As mechanisms of thalidomide teratogenicity have been extensively reviewed elsewhere, they will only be covered here in brief:
(a) Angiogenesis. Thalidomide's anti-angiogenic effects provide insight into the predilection for limb deformities in its teratogenic phenotype. Developing limb buds comprise an immature vessel network that is hypersensitive to thalidomide's anti-angiogenic effects. 51 Thalidomide induces loss of newly formed vessels at critical stages in limb development before the onset of malformations. 51 Changes in vasculature appear to precede changes in gene expression, cytostatic effects and cell death in the developing limb. This suggests defects in vascular development are an upstream event in teratogenicity.
(b) Oxidative stress. There is much evidence linking thalidomide teratogenicity to oxidative stress. Bioactivation of thalidomide induces glutathione depletion and DNA-oxidation consistent with the capacity to generate reactive oxygen species. 57 Interestingly, the threshold for thalidomide-induced free-radical generation and embryonic DNA-oxidation is much lower in rabbits than mice, corresponding with greater sensitivity to dysmorphogenesis. Pretreatment of rabbits with the free-radical spin trapping agent, alpha-phenyl-N-t-butylnitrone abolishes thalidomide-induced DNA-oxidation and teratogenicity. 57 The induction of oxidative stress in developing limb buds (potentially compounded by tissue hypoxia) induces alterations pro-survival signaling pathways including NF-kB, 58 (c) Dysfunction of the cereblon/DNA-binding protein 1 ubiquitinligase complex. Cereblon is a ubiquitously expressed protein that was identified as a candidate gene in a mild form of autosomal recessive, non-syndromal mental retardation. 59, 60 Cereblon binds voltage-gated chloride channels in the retina 61 and calciumactivated potassium channels in the brain. 62 It also modulates AMP-activated protein kinase activity. 63 In autosomal recessive, non-syndromal mental retardation, a truncating cereblon point mutation interrupts C-terminal myristoylation and phosphorylation sequences, potentially disrupting intracellular localization and signaling activity, respectively. 59, 60 Cereblon is required for the E3 ubiquitin-ligase activity of a multi-protein complex containing DNA-binding protein 1 and Cullin 4 ( Figure 4) . Thalidomide was recently demonstrated to directly modulate FGF-mediated angiogenesis via a cereblondependent pathway. 53 Using thalidomide to 'pull down' potential drug targets from crude cell extracts, Ito et al. 53 identified cereblon as a thalidomide-binding protein. The antagonism of cereblon by thalidomide was subsequently shown to be necessary but insufficient to induce teratogenicity in Zebrafish and chick embryos. In the Zebrafish model, thalidomide-induced teratogenicity could be phenocopied by cereblon knockdown and rescued by overexpression of a thalidomide-insensitive cereblon mutant protein. 53 Thalidomide exposure or cereblon knockdown resulted in reduced FGF expression in the apical ectodermal ridge, providing a mechanistic link between thalidomide, cereblon and FGF-mediated angiogenesis in teratogenicity.
Although the characterization of cereblon as a thalidomidetarget provided much insight into teratogenic mechanisms, the role of complementary pathways remains undefined. In the human, cereblon mutations causing autosomal recessive, nonsyndromal mental retardation do not associate with limb defects. 60 Conversely, persons suffering from thalidomideinduced dysmelia do not demonstrate intellectual disability. 1 As the protein structure of cereblon is highly conserved, thalidomide should not discriminate between rodent and human (or Zebrafish) protein. 53 Thus, the well described associations between speciesspecific thalidomide metabolism and angiogenic effects are not well explained by the cereblon-model of teratogenicity. Another caveat to the interpretation of Zebrafish modeling is the supraphysiological thalidomide dosing required to induce antiangiogenic and teratogenic phenotypes. Myeloma patients receive 50-200 mg/day of thalidomide. A dose-escalation study in elderly prostate cancer patients recorded maximum steadystate plasma concentrations of 11 mg/ml (B40 mM) in persons receiving 1.2 g of thalidomide daily. 64 However, Ito et al.
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reported dysmorphogenesis with 400 mM of thalidomide applied directly to dechorionated embryos, diluted from a 400 mM DMSO stock solution. As thalidomide is relatively insoluble, repeated cycles of heating (to 65 1C) and agitation were required to solubilize thalidomide, introducing the potential for pre-analytical drug modification. Others have reported Zebrafish embryos to be much less sensitive to thalidomide application. For example, Cheng et al. 65 reported that thalidomide concentrations of 2 mg/ml (B7-8 mM) were the minimum requirement to induce vascular deformities in transgenic fli1a: EGFP Zebrafish. As both investigators used similar methodology, the reasons for this 10-fold discrepancy in potency are unclear. In either case, the concentrations used are much higher than those measured in human subjects.
Although it is apparent that cereblon is a potentially important IMiD target, there are still many unanswered questions regarding mechanisms of thalidomide embryotoxicity. In particular, the grossly divergent interspecies sensitivity to teratogenesis is unresolved. If a pathway linking thalidomide-related cereblon inhibition to species-specific oxidative stress were elucidated, this might finally provide a unifying model (Figure 4 ).
EVIDENCE FOR GENETIC AND EPIGENETIC EFFECTS OF IMIDS
Although not mutagenic, 66 thalidomide intercalates DNA. 67, 68 Specifically, S( À ) thalidomide is predicted to intercalate into the major groove of the DNA-double helix structure at purine sites (with greater affinity for guanine over adenine) where its glutarimide moiety oriented in a 3 0 -direction. 56 The preferential affinity of thalidomide for guanine nucleotides potentially explains differential regulation of genes bearing GC-rich gene promoters. The transcription factor Sp1 binds GC-boxes within promoter regions and docks within the major groove of DNA that would be occupied by intercalated thalidomide. 69, 70 Candidate genes regulated by Sp1 include insulin-like growth factor and its receptor, insulin receptor substrate-1, FGF-2, FGF receptors and several integrins. As these have a central roles in angiogenesis and embryo development, modulation of gene expression via intercalation at GC-rich promoters has been proposed as a mechanism for thalidomide teratogenesis (reviewed in Stephens et al. 56 ). The DNA-intercalation model provides a conceptual framework for how thalidomide might reduce the efficiency of transcription at GC-rich promoters. However, emerging evidence suggests the IMiDs epigenetically promote the transactivation of genes at the same GC-rich loci. Lenalidomide and pomalidomide induce growth arrest in selected myeloma and B-cell lymphoma cell lines. This correlates with the induction of the cell cycle regulator p21 WAF-1 and concomitant inhibition of cyclin-dependent kinases, hypo-phosphorylation of Rb and G 0 -G 1 arrest. 71 Pomalidomide rapidly upregulates CDKN1A mRNA expression via p53-independent recruitment of Sp1 to a proximal GC-rich region in the CDKN1A promoter (Figure 5a) . 72 Sp1 recruitment occurs in the absence of a change in absolute Sp1 levels and is facilitated by the acetylation of histone H3 on lysines 9 and 14. As the IMiDs do not inhibit histone deacetylases, an indirect mechanism whereby recruitment of the histone demethylase, LSD-1 to H3K9 was suggested. 72 In this model, the acetylation of H3K9/14 is coregulated by LSD-1 demethylation at the same loci.
Epigenetic mechanisms are also implicated in IMiD-related modulation of cytokine expression (Figure 5b) . 73 Cytokine receptor ligation activates intracellular signaling through the JAK/STAT pathway. STAT target genes include the suppressor of cytokine signaling (SOCS) genes that attenuate JAK/STAT activity. 74 SOCS1 is a negative regulator of IFN-g, IL-2 and IL-6. Hypermethylation of the SOCS1 promoter is reported in myeloma patients, leading to augmented expression of IL-6, a potent plasma cell growth factor. 75 Pomalidomide upregulated myeloma cell SOCS1 expression concomitant with demethylation of its silenced promoter region. 73 Demethylation of the SOCS1 promoter by pomalidomide or 5-azacitidine correlated with increased myeloma cell sensitivity to subsequent lysis by cytotoxic T lymphocytes. Interestingly, the epigenetic modulation of SOCS1 was tumor specific, as the promoter methylation was unchanged in effector lymphocyte populations. 73 
ACTIVITY IN MDS WITH DEL 5Q
MDS refers to a group of clonal bone marrow stem-cell disorders characterized by ineffective hematopoiesis and potential transformation to acute myeloid leukemia. MDS with associated deletion of the long arm of chromosome 5 (del 5q) is an MDS subtype characterized by refractory macrocytic anemia, well preserved thrombopoiesis and low bone marrow blasts. 76 Unlike other MDS, 5q-syndrome has a high response rate to lenalidomide, including cytogenetic remissions and improved erythropoiesis. 77 The clinical phenotype of MDS with del 5q is specifically mapped to loss of a common deleted region (CDR) on chromosome 5. 78 This CDR provides a list of 40 genes implicated in the biology of 5q-syndrome and therefore a template for the discovery of lenalidomide-responsive elements. In a seminal paper, Ebert et al. 79 used an RNA-mediated interference approach to interrogate the CDR. They identified ribosomal protein (RP) S14 haploinsufficiency as a key determinate of the erythroid differentiation defect in MDS with del 5q. This correlated well with prior descriptions of heterozygous germline mutations for several other RPs in patients with Diamond-Blackfan anemia, a congenital bone marrow failure syndrome. 80, 81 The erythroid defect conveyed by RPS14 loss is p53 dependent, indicating that activation of the p53 tumor suppressor pathway is necessary for RP haploinsufficiency to induce anemia. 82, 83 Although RP haploinsufficiency contributes to the p53-dependent anemia of MDS with del 5q, other genes are implicated in the generation of dysplastic megakaryocytic hyperplasia and thrombocytosis. In particular, loss of microRNA-145 in the CDR results in increased expression of the transcription factor Fli-1 (ref. 84 ). Fli-1 overexpression causes a shift from erythropoiesis to megakaryopoiesis to co-operate with RPS14 deletion in the induction of anemia while promoting platelet production.
The predominant clinical response to lenalidomide in MDS is improved erythropoiesis with a significant proportion of patients achieving independence from red cell transfusions. 77 This is associated with cytogenetic improvement, but occurs at the expense of thrombocytopenia and neutropenia. Despite detailed insight into the molecular mechanism of anemia and thrombocytosis in MDS with del 5q, the mechanism of lenalidomide activity remains something of an enigma as RPS14 is not an IMiD -responsive gene. 85 Gene-expression profiling of lenalidomide-treated del 5q erythroblasts revealed significant upregulation of only one CDR gene, SPARC.
85 SPARC regulates interactions with the extracellular matrix, mediating antiproliferative and anti-angiogenic effects in common with IMiDrelated activity. An alternative hypothesis is that lenalidomide further downregulates the function of haploinsufficient proteins coded in the CDR by post-transcriptional and post-translational mechanisms. This might explain selective toxicity for del 5q cells over normal cells with a diploid gene complement at the same locus. For example, del 5q cells are haplodeficient for the protein phosphatases Cdc25C and PP2A and the expression of these genes is lower in MDS with del 5q than with other MDS. 86 Lenalidomide increases the retention of inhibitory phosphorylation residues on cell cycle regulators targeted by Cdc25C and PP2A. 86 This correlates with potent inhibition of recombinant human Cdc25C phosphatase activity by lenalidomide in the nanomolar concentration range in vitro.
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Lenalidomide's effects on PP2A activity appear to be indirect, as they cannot be demonstrated on purified protein in the same assays. As Cdc25C and PP2A regulate the cell cycle, antagonism by lenalidomide explains the selective induction of growth arrest and apoptosis in del 5q cells compared with their normal counterparts.
The erythroid phenotype of MDS with del 5q is p53 dependent. 82 Moreover, neoplastic escape from lenalidomide in vivo is associated with selection for sub-clones with mutant p53. 87 Ribosomal biogenesis occurs in the nucleolus, which also provides a sink for the sequestration of the p53 ubiquitin ligase, MDM2 (Figure 6a ). Nucleolar stress due to a range of causes including ribosomal protein deficiency results in the dispersion of free RPs that are able sequester MDM2 independently of its coregulator ARF. The sequestration of MDM2 allows stabilization of p53. Lenalidomide might therefore attenuate the severity of dyserythropoiesis indirectly by either reducing ribosomal stress or promoting p53 degradation. The suppressive effects of lenalidomide on mRNA translation 25 potentially reduces the biosynthetic demands of a cell on haploinsufficient ribosome biogenesis. Lenalidomide also promoted degradation of p53 in the context of 5q deletion by antagonising PP2A-enhanced ubiquitin-mediated clearance of MDM2. 88 Thus, it is possible that lenalidomide treatment reduces ribosomal stress and the p53 response thereof to ameliorate dyserythropoiesis (Figure 6a ). The observation that lenalidomide can destabilize p53 is clinically significant, as p53 suppression is a highly oncogenic effect. IMiD-mediated p53 suppression provides a mechanistic explanation for the recently published observation that prolonged exposure to lenalidomide is associated with the development of second cancers (discussed further below).
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ACTIVITY IN MM AND MATURE B-CELL NEOPLASMS
MM is a malignancy of immunoglobulin producing plasma cells associated with systemic toxicities including renal failure, anemia, immunoparesis and destructive skeletal lesions. 93 The mechanism of action of IMiDs in MM is complex and likely reflects the sum-total of a range of independent targets including direct toxicity to MM cells, disruption of the protective bone marrow microenvironment and augmentation of host-mediated anti- tumor immunity. Myeloma is a clinically and molecularly heterogeneous disease. 93, 94 Despite this heterogeneity, IMiDresponsiveness is a defining feature of the majority of MM at presentation; a phenotype shared with selected other mature 'post-germinal center' B-cell malignancies. 95 This potentially indicates that the IMiDs target fundamental aspects of mature B-cell biology.
(a) Myeloma cell autonomous effects An intriguing property of the IMiDs is anti-tumor activity with selectivity for neoplasms of mature B-cell origin. In rare instances this is explained by 5q loss, 71 however, a more complex molecular interaction is implicated in the majority of cases. Mature B-cell malignancies including MM and diffuse large B-cell lymphoma of activated B-cell phenotype show dependence on constitutive NF-kB signaling and upregulation of interferon regulatory factor (IRF)-4 ( Figure 6b) . 95 Mutually permissive 'feed-forward loops' linking IRF-4 to cMYC implicate the former as an 'oncogene of addiction' in MM. 96 MYD88 is an adaptor protein that mediates interleukin and toll-like receptor signaling. Gain-of-function MYD88 mutations and copy number amplification are observed in more than half of diffuse large B-cell lymphoma of activated B-cell phenotype and are associated with increased IRF-4 expression. 97 Genomic profiling of MM revealed frequent mutations of genes implicated in NF-kB signaling and IRF-4 itself. 94 Thus, diverse oncogenic mechanism with the net effect of NF-kB and IRF-4 activation link these IMiD-responsive diseases.
Recent evidence suggests that IMiDs can downregulate the NF-kB/IRF-4 axis at multiple levels. In MM, antagonism of the eIF4E translational axis decreases CCAAT/enhancer-binding proteinb protein expression to impair transcription at the IRF-4 locus. 25 In diffuse large B-cell lymphoma of activated B-cell phenotype, lenalidomide relieves the suppressive effects of constitutive MYD88 signaling on interferon-b by downregulating IRF-4 (ref. 95) . The ensuing lethal type-1 interferon response mediates apoptosis through the extrinsic (death receptor) pathway. Similarly, Mitsiades et al. 98 correlated IMiD-induced downregulation of NF-kB with activation of the extrinsic apoptotic pathway and sensitization to death-receptor agonists including TNF-related apoptosis related ligand in human myeloma cell lines.
Interestingly, the direct cytostatic and apoptotic effects of IMiDs are less evident in lymphomas and myelomas after depletion of cereblon, linking this mediator of teratogenicity to anti-tumor effects. 95, 99, 100 Acutely, shRNA-mediated cereblon knockdown induces cytostatic and apoptotic effects in MM cell lines that correlates with a reduction in IRF-4 expression. 100 Those MM cells surviving sustained cereblon knockdown are lenalidomide resistant when compared with their parental counterparts. Conversely, prolonged (4 to 6 months) in vitro treatment with lenalidomide generates IMiD-resistant MM cell lines that show reduced cereblon expression relative to non-lenalidomide treated controls. 99, 100 The resistance phenotype is specific to IMiDs, as lenalidomide-conditioned MM cell lines remained sensitive to apoptosis induction by dexamethasone. Cereblon mRNA expression was also reportedly reduced in primary patient MM samples with clinically resistant disease following a period of lenalidomide therapy. 100 However, the effects of cereblon knockdown did not entirely phenocopy IMiD treatment. For example, gene expression profiling of OPM2 MM cells identified 2398 differentially regulated genes following lenalidomide treatment, but only 123 were concordant with the cereblon knockdown gene set of 768 genes. 100 Thus, although it is apparent that cereblon mediates some of the cell-intrinsic activity of IMiDs in MM, complementary mechanisms and other molecular targets are likely to be at play. This is consistent with observations in teratogenicity, where cereblon binding is necessary but insufficient to explain the teratogenic phenotype. of conventional therapeutics. 101, 102 Elaborate co-culture systems have defined both direct interactions with bone marrow stromal cells and humoral components of cytokine networks as essential to MM viability. 101, [103] [104] [105] In particular, osteoclastogenic cytokines of the TNF-family and IL-6 are implicated in myeloma cell growth and skeletal destruction. 102, 106 Paracrine and autocrine interleukin networks combine with cell adhesion molecules to activate intracellular pro-survival pathways including PI3K/AKT, NF-kB and RAS/MAPK. 107, 108 Myeloma cell adherence to bone marrow stroma also upregulates VEGF secretion to promote angiogenesis. 48 By downregulating cytoprotective cytokines (for example, IL-1b, IL-6, IL-10 and VEGF), the IMiDs may disrupt protection by the microenvironment, sensitizing myeloma to concurrent cytotoxic therapies. 109 As conventional therapies are initially successful in debulking a high proportion of the myeloma burden, the bone marrow niche is postulated to rescue clonogenic myeloma stem cells ultimately responsible for disease relapse. 110 Although the literature on the identification of myeloma stem cells are somewhat nebulous and without consensus, studies have eluded to several populations of myeloma cells that have clonogenic capacity. These include the CD138 À CD27 þ cells that are lenalidomide, dexamethasone, cyclophosphamide and bortezomib resistant with a high level of hedgehog signaling. 111, 112 Furthermore, a small population of CD34 þ CD45 low myeloma cells has been shown to have clonogenic properties in NOD/SCID mice. 113 'Side-population cells' defined by the capacity to efflux Hoechst 3342 stain, 114 have also been identified as a source of stem-cell like chemoresistant cancer-initiating cells. The proliferation and survival of MM side-population cells is augmented by bone marrow stroma through pathways that are suppressible by thalidomide and lenalidomide. 110 Lenalidomide also reduces the clonogenic potential of myeloma side-population cells. 110 This indicates that suppression of the myeloma 'stem-cell' may be an important facet to IMiD activity, particularly in the prevention of relapse from minimal residual disease states (for example, following autologous stem-cell transplantation).
(c) Immunological disease control Hematological malignancies, particularly MM are characterized by progressive immune cell dysregulation, of which T-and NK-cell suppression is well described. [115] [116] [117] Lenalidomide's ability to potentiate T-and NK-cell activation 37, 38, 40 has resulted in exploratory studies elucidating the role of IMiDs in the immunological control of MM. NK-cell interaction with target cells involves a complex set of activating and inhibitory receptors. Activating receptors involved in MM cell recognition and lysis are largely governed by NKG2D, with a lesser role for DNAM-1 and NKp46. 118 Interestingly, IMiDs do not appear to alter the expression of these receptors to confer functional changes in NK-cell activity. 40, 118, 119 IMiDs upregulate CD16 expression on NK cells to increase antibody-dependent cell cytotoxicity against MM. 120, 121 It is becoming evident that IMiDs are able to decrease the activation threshold of NK-cell cytotoxicity through modulation of inhibitory receptor interactions. MM-induced expression of the programmed cell death receptor 1 inhibits NKcell cytotoxicity. 122 Treatment with lenalidomide reduces programmed cell death receptor 1 ligand on MM cells and thus sensitizes MM cells to lysis by autologous NK cells. 122 Killer-cell Immunoglobulin-like receptors (KIR) are well described as the major functional inhibitory receptors on NK cells. 123 As MM cells express high levels of the KIR ligand, HLA class I, it is likely that this interaction contributes to NK-cell dysfunction in vivo. 124, 125 IMiDs are able to reduce the expression of KIR on NK cells. 119 Furthermore, a recent study demonstrated the therapeutic efficacy of combination IMiD and anti-KIR blocking therapy in a mouse model of MM. 125 The contribution of T-cells to immune-mediated control of MM in vivo has been a difficult question to address, with conflicting reports characterizing both impaired/exhausted and activated clonal expansions of MM-specific T-cells in MM patients. [126] [127] [128] [129] There is agreement, however, on the responsiveness of T-cells to immunomodulatory agents. The stimulatory effect of IMiDs on T-cell function is driven by PI3K-mediated activation of nuclear factor of activated T-cells-2. 37, 130 This results in increased production of IL-2 and NK-cell stimulation. 37, 40 Further to this, IMiDs appear to polarize T-cells towards a Th-1 phenotype through costimulation, resulting in the production of IFN-g and suppression of IL-10. 131, 132 The first study to show protective antitumor immunity by IMiDs in conjunction with whole-tumor cell vaccination was demonstrated in a CT-26 colon mouse model. 33 More recently, Noonan et al. 34 showed single-agent lenalidomide therapy in MM patients augmented endogenous MM-specific CD8 T-cell responses. 34 Both Th-17 and regulatory T-cells have a pathogenic role in MM, with higher T-regulatory cells conferring poorer outcomes in MM patients. 133, 134 The ability of IMiDs to reduce Th-17 cells, and inhibit the generation and function of Foxp3 T-regulatory cells may result in the mediation of T-cell responses against MM. 34, 135 
CLINICAL TOXICITIES PROVIDE MECHANISTIC INSIGHT INTO IMID BIOLOGY
The differing side effect profiles of thalidomide and its IMiD derivatives highlight important biological distinctions between these closely related compounds not merely explained by issues of potency. Elucidation of the mechanisms responsible for divergent clinical toxicities could potentially inform the biology of tumor-specific responses to the respective analogues. The major cumulative dose-limiting toxicity of thalidomide is peripheral neuropathy 136 with minimal bone marrow suppression. Although lenalidomide is more potent than thalidomide (for example, in TNFa suppression assays), it does not cause neuropathy. 89 Rather, lenalidomide suppresses normal hematopoiesis resulting in neutropenia and thrombocytopenia. Pomalidomide also causes neutropenia, with a lower incidence of neuropathy than thalidomide. 137 All of the IMiDs are prothrombotic, with prophylactic anticoagulant therapy often administered concurrent to the IMiDs to prevent venous thromboembolic disease. The greatest emerging concern with chronic lenalidomide exposure is a measurable increase in the incidence of second primary malignancies. [89] [90] [91] [92] (a) Peripheral neuropathy Neuropathy occurs in most patients receiving chronic thalidomide therapy with an actuarial incidence of over 70% at 12 months. 136 The etiology of thalidomide-induced neuropathy is multifactorial, as patients often have pre-existing nerve damage and many receive concurrent neurotoxic therapies. In particular, the combination of thalidomide with bortezomib is associated with a high risk of nerve damage. 138 However, the potent newgeneration proteasome inhibitor carfilzomib is not neuropathic, indicating that the neurotoxicity of bortezomib may be 'off target' inhibition of other serine proteases. 139 HtrA2/Omi was identified as a non-proteasomal bortezomib target that is spared by carfilzomib and protects neurons from oxidative stress. 139 Thus, thalidomide-induced free-radical generation 57 and bortezomibinduced depletion of neuroprotective serine proteases (for example, HtrA2/Omi) could combine to cause the mitochondrial toxicity observed in neuropathic states. Indeed, genomic profiling identified a single-nucleotide polymorphism of glutathione S-transferase theta-1 (GSTT1) as predictive of neuropathy in a cohort of myeloma patients receiving thalidomide. 140 As GSTT1 is a cellular regulator of reactive oxygen species, this further implicated thalidomide-induced oxidative stress in the etiology of nerve damage.
(b) Hematological toxicities Neutropenia and the risk of sepsis is a major dose-limiting toxicity of lenalidomide. Lenalidomide treatment is also associated with impaired stem-cell mobilization for autologous CD34 þ collection before transplantation in MM. 141 This is despite the observation that IMiDs induce the expansion of CD34 þ bone marrow progenitors in vitro. 142 However, the transcriptional changes that evoke CD34 þ proliferation in vitro are also associated with a differentiation block within the granulocytic lineage. 143 This apparent 'maturation arrest' is associated with downregulation of the transcription factor PU.1, and results in a relative excess of promyelocytes. Promyelocytes are rich in prothrombotic mediators including cathepsin G, a platelet agonist implicated in the pathogenesis of disseminated intravascular coagulation complicating acute promyelocytic leukemia. 144 Therefore, IMiD-induced changes in granulocyte maturation may directly contribute to an increased risk of venous thrombosis. 143 Other well-described IMiD activities are pro-coagulant. Suppression of COX-2 has been clearly implicated in adverse thrombotic events in patients treated for non-malignant inflammatory conditions. 26, 145 On-target suppression of angiogenesis is also pro-thrombotic, as endothelial cells that become stressed in response to VEGF withdrawal release a range of pro-coagulant mediators. 44, 146 A targeted genetic screen of myeloma patients identified singlenucleotide polymorphisms associated with thalidomideassociated thrombosis in genes and pathways important in drug metabolism, DNA-repair and cytokine regulation. 146 The authors suggested that susceptibility to IMiD-associated thrombosis was secondary to rapid dissolution of myeloma in the context of apoptosis induction by concurrent DNA-damaging stimuli. The thrombogenicity of IMiDs is therefore multifactorial and contributed to by underlying malignancy and associated treatments.
(c) Lenalidomide and second primary malignancies With the benefit of longer myeloma-related progression free survival, patients receiving chronic lenalidomide maintenance therapy have an increased risk of both hematopoietic and solid organ cancers. 89 Several major clinical studies identified an increased incidence of second primary malignancies in MM patients receiving chronic 'maintenance' lenalidomide. [90] [91] [92] The incidence of second cancers in these studies was as high as 7% with a hazard ratio close to double that of placebo-treated controls. Elucidation of the precise molecular oncogenic mechanisms is confounded by prior or concurrent exposure to genotoxic agents, in particular the alkylator melphalan. Second primary cancers have not yet been associated with other IMiDs, and lenalidomide does not appear to accelerate the progression of MDS with del 5q to acute leukemia. 89 However, as the 'danger signal' from these large lenalidomide trials has only recently emerged, mechanistic insights remain speculative. Lenalidomide is not considered directly mutagenic, but could plausibly synergize with DNA-damaging cytotoxics in oncogenesis. For example, lenalidomide destabilizes p53, 88 an important tumor suppressor in the context of DNA-damage. This might also explain the lack of an association between thalidomide and second cancers, as it is less potent in this regard. However, all of the IMiDs bind cereblon and dysfunction of the cereblon/DDB-1 ubiquitin-ligase complex might also impair the DNA-damage response, as DDB-1 functions in nucleotide excision DNA-repair. 147 Elucidation of the capacity for IMiDs to potentiate mutagens requires urgent scientific attention in order to inform the safe delivery of IMiD/chemotherapy combinations in the clinic.
CONCLUSIONS
Despite their simple chemical structures, thalidomide and its analogues exhibit pleotropic immunomodulatory and anti-neoplastic effects. This conveys remarkable clinical efficacy in clearly defined disease entities, specifically granulomatous inflammation, mature B-cell neoplasms and MDS with del 5q. The molecular mechanisms of IMiD activity are likely to be both divergent and complementary across these distinct diseases. In particular the combined ability to modulate multiple targets from the level of the epigenome to post-translational protein modulations and systemic cytokine networks highlights the complexity of IMiD biology. Unfortunately, the beneficial properties of IMiDs may be inseparable from serious clinical toxicities including teratogenicity, secondary malignancy, myelosuppression and nerve-damage, ostensibly because they are mediated by shared molecular targets. It is hoped that the next chapter in the 'thalidomide saga' 1 will be the identification of new targets that can be therapeutically manipulated by novel non-IMiD pharmaceuticals to derive clinical benefit without toxicity.
